noscript

News and Announcements

Actinogen Medical Investor Research Update

  • Published October 13, 2016 11:22AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

September 27, 2016

Actinogen Medical (ASX:ACW) met again with Baker Young Stockbrokers to discuss Xanamem™’s past research and recent initiation of XanADu, a Phase II clinical trial in Alzheimer’s disease (AD).

Best Risk vs Reward Play in Alzheimer’s Dementia

Baker Young maintains coverage of Actinogen Medical with a BUY recommendation and value ACW $0.39 per share base case and $1.12 per share optimistic case using the probability weighted DCF methodology.

Alastair Murray
Analyst, Baker Young Corporate

We see XanADu, the Phase II trial of Xanamem™ for the treatment of mild Alzheimer’s disease positioning Actinogen amongst significantly larger peers (see Table inside report). Going forward Actinogen has a strong cash position to progress through the pivotal Phase II clinical trial, which the company hopes will show Xanamem™ to be an effective and safe treatment for mild Alzheimer’s disease. We believe positive results from this Phase II trial will likely result in a significant partnering transaction (potential for a total deal size of up to $1B upfront & milestones + royalties) given the current unmet market need, comparable similar transactions and Big Pharma’s desire to bring new effective treatments for dementia to market. We believe ACW at current levels represents compelling value on a risk-reward basis”

To view the Baker Young Report, please click on the button below.

Capital Insights
The Index Approach in Early-Stage Venture Capital: Reconsidered

The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]

Capital Insights
The Future Is Now: The Evolution of Dealflow with Wholesale Investor

If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]

Join over 45,000+ sophisticated investors

Join Now